X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3431) 3431
Publication (536) 536
Book Review (58) 58
Book Chapter (19) 19
Conference Proceeding (8) 8
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2197) 2197
index medicus (2122) 2122
immunotherapy (1380) 1380
animals (1262) 1262
immunology (1120) 1120
oncology (1045) 1045
ctla-4 (1012) 1012
cancer (960) 960
female (816) 816
ctla-4 antigen (799) 799
melanoma (799) 799
male (781) 781
ipilimumab (769) 769
mice (746) 746
t cells (660) 660
lymphocytes (611) 611
antibodies, monoclonal - therapeutic use (602) 602
ctla-4 antigen - antagonists & inhibitors (548) 548
ctla-4 protein (528) 528
ctla-4 antigen - immunology (525) 525
ctla-4 blockade (516) 516
metastatic melanoma (514) 514
lymphocytes t (507) 507
care and treatment (493) 493
antigens (487) 487
middle aged (460) 460
t-lymphocytes - immunology (434) 434
tumors (433) 433
abatacept (423) 423
immunotherapy - methods (413) 413
expression (400) 400
pd-1 (391) 391
antigens, cd (382) 382
adult (381) 381
melanoma - drug therapy (381) 381
immune checkpoint (376) 376
cytotoxicity (359) 359
programmed cell death 1 receptor - antagonists & inhibitors (357) 357
research (351) 351
article (346) 346
dendritic cells (338) 338
t-cells (336) 336
regulatory t-cells (335) 335
aged (332) 332
neoplasms - immunology (331) 331
antineoplastic agents - therapeutic use (322) 322
immunoconjugates (313) 313
activation (309) 309
immune system (309) 309
analysis (303) 303
metastasis (299) 299
nivolumab (299) 299
health aspects (294) 294
t-lymphocytes, regulatory - immunology (293) 293
apoptosis (287) 287
treatment outcome (285) 285
antibodies, monoclonal - adverse effects (284) 284
chemotherapy (284) 284
therapy (284) 284
patients (282) 282
immune response (281) 281
medicine, research & experimental (275) 275
mice, inbred c57bl (268) 268
antibodies, monoclonal - pharmacology (257) 257
melanoma - immunology (255) 255
antibodies (253) 253
ctla-4 antigen - metabolism (253) 253
chemical and pharmacologic phenomena (252) 252
blockade (250) 250
clinical trials (249) 249
transplantation (247) 247
programmed cell death 1 receptor - immunology (243) 243
monoclonal antibodies (237) 237
pd-1 protein (237) 237
cytokines (235) 235
drug therapy (234) 234
neoplasms - therapy (234) 234
antigens, cd - immunology (233) 233
flow cytometry (232) 232
autoimmunity (230) 230
cell biology (227) 227
cancer therapies (226) 226
t-lymphocytes - drug effects (218) 218
in-vivo (217) 217
pd-1 blockade (216) 216
antitumor immunity (215) 215
lymphocyte activation - drug effects (215) 215
medicine & public health (215) 215
mice, inbred balb c (215) 215
cd28 (214) 214
t cell receptors (213) 213
medical research (212) 212
gene expression (204) 204
b7-h1 antigen - antagonists & inhibitors (199) 199
surgery (199) 199
survival (198) 198
neoplasms - drug therapy (196) 196
open-label (193) 193
medicine (192) 192
cells, cultured (191) 191
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3367) 3367
German (16) 16
Chinese (14) 14
Japanese (14) 14
French (13) 13
Czech (3) 3
Danish (3) 3
Polish (3) 3
Hebrew (1) 1
Hungarian (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1136 - 11
Journal Article
Journal Article
Journal Article
Journal Article
DIABETES, ISSN 0012-1797, 02/2017, Volume 66, Issue 2, pp. 448 - 459
The introduction of beta-cell autoantigens via the gut through Lactococcus lactis (L. lactis) has been demonstrated to be a promising approach for diabetes... 
RESPONSES | TGF-BETA | THERAPY | DENDRITIC CELLS | EFFICACY | TEPLIZUMAB | VACCINE | ENDOCRINOLOGY & METABOLISM | CTLA-4 | FOXP3(+) | DELIVERY | Forkhead Transcription Factors - immunology | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | Transforming Growth Factor beta - drug effects | Immune Tolerance - immunology | Interleukin-10 - secretion | Disease Models, Animal | Immune Tolerance - drug effects | Transforming Growth Factor beta - immunology | Glucose Tolerance Test | CTLA-4 Antigen - drug effects | Lymphocyte Activation | Diabetes Mellitus - metabolism | Pancreas - drug effects | Pancreas - pathology | Antibodies, Neutralizing - pharmacology | CTLA-4 Antigen - immunology | Lactobacillus - metabolism | Antibodies - pharmacology | Blood Glucose - drug effects | T-Lymphocytes, Regulatory - drug effects | Animals | CD3 Complex - immunology | Proinsulin - secretion | Mice, Inbred NOD | Mice | Blood Glucose - metabolism | CD4-Positive T-Lymphocytes - drug effects | Viral antibodies | Usage | Care and treatment | Lactococcus | Rodents | Antibodies | Genetic aspects | Dosage and administration | Research | Diabetes | T cells | Basic Medicine | Immunologi inom det medicinska området | Medical and Health Sciences | Medicin och hälsovetenskap | Immunology in the medical area | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 2014, Volume 211, Issue 4, pp. 715 - 725
Journal Article
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article